

AN 04/1505

REC'D 16 NOV 2004

WIPO PCT

PA 1248

# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

**UNITED STATES DEPARTMENT OF COMMERCE**

**United States Patent and Trademark Office**

**October 25, 2004**

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.**

**APPLICATION NUMBER: 60/515,267**


**FILING DATE: October 29, 2003**

## **PRIORITY DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS**



  
**VIELKA BROWN**  
Certifying Officer


Docket Number: 224997

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).


INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Alexander A Royal Alexander	KHROMYKH HALL	The Gap, Queensland, Australia Graceville, Queensland, Australia
<input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto.		
TITLE OF THE INVENTION (280 characters max)		
WEST NILE VIRUS VACCINE		
CORRESPONDENCE ADDRESS		
Direct all correspondence to:		
<input checked="" type="checkbox"/> Customer Number 23460  23460	<input type="checkbox"/> Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 U.S.A.	
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification (including any claims and abstract)	Number of Pages: 27	<input type="checkbox"/> Power of Attorney
<input checked="" type="checkbox"/> Drawings	Number of Sheets: 2	<input type="checkbox"/> Assignment
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input type="checkbox"/> CD(s), Number
		<input type="checkbox"/> Other (specify)
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		
<input type="checkbox"/> A check or money order is enclosed to cover the filing fee(s).		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fee(s) or credit any overpayment to Deposit Account Number 12-1216. A duplicate copy of this communication is enclosed for that purpose.		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any deficiencies in filing fees to Deposit Account Number 12-1216. A duplicate copy of this communication is enclosed for that purpose.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government:		
<input checked="" type="checkbox"/> No.		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:		

Respectfully submitted,

  
John Kilyk, Jr., Registration No. 30,763  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: October 29, 2003

**CERTIFICATION UNDER 37 C.F.R. § 1.10 (IF APPLICABLE)**

EL 841125041 US "Express Mail" Mailing Number	October 29, 2003 Date of Deposit
I hereby certify that this Provisional Patent Application, including the materials referred to hereon as being attached or enclosed, is being deposited with the United States Postal Service's "Express Mail Post Office to Addressee" service on the date shown above in an envelope addressed to: Commissioner for Patents, Mail Stop Provisional Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450.	
Peter J Phillips Typed or Printed Name of Person Making Deposit	 Signature of Person Making Deposit

TITLE

## WEST NILE VIRUS VACCINE

FIELD OF THE INVENTION

THIS INVENTION relates to a flaviviral vaccine. More particularly, this  
5 invention relates to a vaccine for protective immunization against West Nile virus.

BACKGROUND OF THE INVENTION

West Nile (WN) virus is a mosquito-transmitted flavivirus that produces a  
potentially fatal disease in humans and horses and has traditionally been  
associated with viral outbreaks in Europe and Africa (1). In 1999 WN virus  
10 appeared for the first time in the New World associated with an outbreak of a fatal  
or debilitating disease in humans and equines and extremely high levels of  
morbidity and mortality in several species of native birds in New York (2). Since  
its introduction into North America, WN virus has spread to most states of the  
USA and to parts of Canada and Mexico via mosquito-bird transmission cycles (3;  
15 [www.cdc.gov/ncidod/dvbid/westnile/index.htm](http://www.cdc.gov/ncidod/dvbid/westnile/index.htm)). There is now an urgent need for  
an effective vaccine for veterinary and medical prophylaxis.

Kunjin (KUN) virus is a genetically stable Australian flavivirus originally  
shown to be very closely related antigenically (by virus neutralization tests and  
monoclonal antibody binding studies) to the Sarafend strain of WN virus (4, 5)  
20 and genetically to the prototype Ugandan strain (6, 7). When the North American  
WN virus strain NY99 was isolated, comparative studies (2, 7) revealed 98 to  
99% amino acid homology with KUN virus throughout the coding sequence,  
compared to 93% homology for the Ugandan strain. Because of the homology  
with WN NY99 and other lineage 1 strains of WN virus (8), KUN virus was  
25 arbitrarily re-classified as a subtype of WN virus by the International Committee  
for the Taxonomy of Viruses (9). However, unlike WN virus, KUN produces only  
rare non-fatal cases of human and equine disease (10). Indeed, comparative  
studies of the New York West Nile strain and KUN virus have revealed that 1000-  
10,000 fold more infectious virus of the latter is required to produce disease in  
30 adult mice by peripheral inoculation (11).

SUMMARY OF THE INVENTION

The invention is broadly directed to use of an infectious flavivirus to  
protectively immunize against at least one other flavivirus.

---

Preferably, a less pathogenic flavivirus is used to immunize against at least one other more pathogenic flavivirus.

In a first aspect, the invention provides a vaccine comprising an isolated nucleic acid capable of producing an infectious Kunjin virus, which upon  
5 administration to an animal, elicits a protective immune response to at least another flavivirus.

In a second aspect, the invention provides a method of immunization including the step of administering an isolated nucleic acid capable of producing an infectious Kunjin virus to an animal to thereby elicit a protective immune  
10 response to at least another flavivirus.

In a third aspect, the invention provides a method of selecting a flavivirus against which Kunjin virus may be used as an immunogen, said method including the steps of:

(i) administering an isolated nucleic acid capable of producing an  
15 infectious Kunjin virus to an animal; and

(ii) determining whether said animal is protectively immunized against infection by at least another flavivirus;

wherein if said animal is protectively immunized against said at least another flavivirus, said flavivirus is selected as another virus against which Kunjin  
20 virus may be used as an immunogen.

In a preferred embodiment, said at least another flavivirus is a strain of West Nile virus other than Kunjin virus.

In a particularly preferred embodiment, said strain of West Nile virus is NY 99 strain.

25 In a fourth aspect, the invention provides a non-human animal immunized according to the method of the second aspect.

In a fifth aspect, the invention provides an immune cell or antigen-presenting cell isolated from an animal immunized according to the method of the second aspect.

30 In a sixth aspect, the invention provides an isolated nucleic acid that is capable of producing infectious Kunjin virus for use as an immunogen, said isolated nucleic acid encoding at least one attenuating mutation in a Kunjin virus non-structural protein encoded thereby.

Throughout this specification, unless otherwise indicated, "comprise", "comprises" and "comprising" are used inclusively rather than exclusively, so that a stated integer or group of integers may include one or more other non-stated integers or groups of integers.

5

#### BRIEF DESCRIPTION OF THE FIGURES

- Figure 1. Replication kinetics of Kunjin virus mutants in C6/36 cells (immortalized mosquito cell line). The Kunjin viruses analyzed in this study are: 250PRO (wild-type virus clone), FLSD (leucine at residue 250 of NS1), 250A (alanine at residue 250 of NS1), 250V (valine at residue 250 of NS1).
- 10 Figure 2. Replication kinetics of Kunjin virus mutants in Vero cells (immortalized african green monkey kidney cell line). The Kunjin viruses analyzed in this study are: 250PRO (wild-type virus clone), FLSD (leucine at residue 250 of NS1), 250A (alanine at residue 250 of NS1), 250V (valine at residue 250 of NS1).

15

#### DETAILED DESCRIPTION OF THE INVENTION

- The present invention, at least in part, arises from the unexpected finding that immunization of mice with a plasmid DNA (pKUN1; 12) encoding full-length Kunjin virus (KUN) cDNA under the control of the cytomegalovirus (CMV) promoter, confers protective immunity against New York 99 strain of
- 20 West Nile virus. Furthermore, inclusion in pKUN1 DNA of a mutation in the KUN NS1 gene ensured significant attenuation of pKUN1-derived virus while inducing protective immunity against KUN virus and the New York strain of West Nile virus without causing disease.

- The present invention provides the first ever report of protective
- 25 immunization by administration of a DNA copy of a flavivirus genome, and more particularly, immunization by a non-pathogenic flavivirus genome (Kunjin) against a far more virulent and pathogenic flavivirus (New York 99 strain West Nile Virus).

- Use of plasmid DNA encoding a functional viral genome as a vaccine
- 30 eliminates a number of concerns associated with preparations of live viral vaccines, including possible contaminations with endogenous viruses during preparation of vaccine in cell cultures, and the instability of enveloped viruses at ambient temperatures.

The invention in one aspect therefore provides use of an isolated nucleic acid that is capable of producing an infectious Kunjin virus as a vaccine for immunization against at least one other flavivirus, preferably a more pathogenic flavivirus.

5       The term "*nucleic acid*" as used herein designates single-or double-stranded mRNA, RNA, and DNA inclusive of cDNA and genomic DNA.

By "*protein*" is meant an amino acid polymer. Amino acids may include natural (*i.e* genetically encoded), non-natural, D- and L- amino acids as are well known in the art.

10       A "*peptide*" is a protein having less than fifty (50) amino acids.

A "*polypeptide*" is a protein having fifty (50) or more amino acids.

As used herein, "*flavivirus*" and "*flaviviral*" refer to members of the family *Flaviviridae* within the genus *Flavivirus*, which contains 65 or more related viral species. Typically, flavivirus are small, enveloped RNA viruses (diameter about  
15 45 nm) with peplomers comprising a single glycoprotein E. Other structural proteins are designated C (core) and M (membrane-like). The single stranded RNA is infectious and typically has a molecular weight of about  $4 \times 10^6$  with an m7G 'cap' at the 5' end but no poly(A) tract at the 3' end; it functions as the sole messenger. Flaviviruses infect a wide range of vertebrates, and many are  
20 transmitted by arthropods such as ticks and mosquitoes, although a separate group of flaviviruses is designated as having no-known-vector (NKV).

Particular, non-limiting examples of flavivirus are West Nile virus, Kunjin virus, Yellow Fever virus, Japanese Encephalitis virus, Dengue virus, Montana Myotis leukoencephalitis virus, Usutu virus, St Louis Encephalitis virus and  
25 Alkhurma virus.

The West Nile virus subgroup somewhat controversially includes Kunjin virus as a sub-type. For convenience and without necessarily agreeing with this classification, according to this specification Kunjin virus is an example of a first West Nile virus strain.

30       It will be appreciated that the present invention contemplates use of an isolated nucleic acid capable of producing an infectious Kunjin virus to protectively immunize against at least one other, more virulent and/or pathogenic flavivirus.

A preferred pathogenic flavivirus is any West Nile virus strain which is capable of causing fatal disease in humans.

New York 99 strain is a preferred example of a second West Nile virus strain.

5        Therefore, in a preferred embodiment the invention provides a vaccine comprising an isolated nucleic acid corresponding to substantially an entire genome of Kunjin virus, which upon administration to an animal, elicits a protective immune response to at least NY99 strain of West Nile virus.

10        In light of the foregoing, it will be appreciated that the present invention may be applicable to using Kunjin virus to immunize against flaviviruses other than West Nile virus.

For example, Kunjin virus could be used to immunize against Japanese Encephalitis Virus (JEV), Yellow Fever Virus (YFV) or St Louis Encephalitis Virus (SLFV), although without limitation thereto.

15        According to one embodiment of the invention, the isolated nucleic acid of the first flavivirus is an RNA molecule corresponding to substantially the entire genome of Kunjin virus.

The RNA molecule may be substantially pure "naked" RNA or may be packaged into virions.

20        According to another embodiment of the invention, the isolated nucleic acid of the Kunjin virus is a cDNA copy of substantially the entire RNA genome of said Kunjin virus.

In a particularly preferred form, the isolated nucleic acid nucleic acid is a cDNA copy of a Kunjin virus genome.

25        In light of the foregoing, it will be understood that "*substantially the entire genome*" encompasses isolated nucleic acids having minor deletions or sequence alterations with respect to the Kunjin virus genome that do not significantly reduce the ability of the isolated nucleic acid to produce infectious virus.

30        In constructing the preferred Kunjin virus cDNA copy described herein, the inventors used an FLSDX clone, the sequence of which differs from the parental MRM61C strain Kunjin virus sequence originally deposited in Genbank.

The sequence differences, both at the nucleotide and amino acid level, are set forth in Table 4.

The invention therefore provides at least a fragment of an isolated Kunjin virus RNA genome or cDNA copy thereof, having at least one of the nucleotide sequence variations set forth in Table 4.

In particular embodiments, nucleotide 554 is C, nucleotide 2556 is G,  
 5 nucleotide 2924 is G, nucleotide 3218 is T, nucleotide 5996 is T, nucleotide 6017 is T and nucleotide 7112 is A, numbered with reference to the published MRM61C sequence.

It will be appreciated that the first flavivirus nucleic acid used in the vaccine of the invention suitably encodes nonstructural proteins NS1, NS2A,  
 10 NS2B, NS3, NS4A, NS4B and NS5.

Preferably, a nucleotide sequence encoding at least one of said non-structural proteins includes at least one attenuating mutation therein.

By "*attenuating mutation*" is meant a mutation that decreases, inhibits, suppresses or otherwise reduces the replication competence of the flavivirus  
 15 and/or its ability to produce disease *in vivo*.

With regard to Kunjin virus, several attenuating mutations are contemplated, although without limitation thereto.

In one particular embodiment, proline residue 250 of the NS1 protein is substituted by an amino acid selected from the group consisting of leucine, valine  
 20 and alanine.

In another particular embodiment, Alanine 30 is substituted by Proline in the nonstructural protein NS2A.

In yet another particular embodiment, Asparagine 101 is substituted by Aspartate in the nonstructural protein NS2A.

25 In still yet another particular embodiment, Proline 270 is substituted by Serine in the nonstructural protein NS5.

It will also be appreciated by persons skilled in the art that other mutations at these positions may be used, as well as mutations and/or deletions in other regions, for example untranslated regions, C gene, prM gene, and E gene,  
 30 providing that they enable the production of infectious Kunjin virus with an attenuated phenotype.

It will also be appreciated that each of the above mutations or substitutions may be alone single or in combination in a Kunjin virus immunogenic nucleic acid of the invention.



According to one form of the present invention, said Kunjin virus nucleic acid is present in a "*genetic construct*" which includes within its scope an "*expression vector*" wherein the isolated nucleic acid of said Kunjin virus nucleic acid is operably linked or operably connected to one or more regulatory sequences that initiate, control, terminate or otherwise regulate transcription and/or translation of the Kunjin virus nucleic acid and/or encoded proteins.

Such an expression construct may be a DNA construct comprising a promoter that facilitates transcription of said Kunjin virus nucleic acid in a mammalian cell.

In another embodiment, an expression construct may be a DNA construct comprising a promoter that facilitates transcription of said Kunjin virus nucleic acid *in vitro* for subsequent delivery as an immunogen.

A preferred promoter for *in vitro* transcription of RNA from a DNA expression construct is an SP6 promoter.

A preferred promoter for *in vivo* transcription of RNA from said DNA expression construct in mammalian cells is a cytomegalovirus (CMV) promoter. However, it will be appreciated that other well-known promoters active in mammalian cells are contemplated, including an SV40 promoter, a human elongation factor alpha promoter and an alpha crystallin promoter, although without limitation thereto.

The genetic construct may further comprise the antigenomic sequence of the hepatitis delta virus ribozyme (HDVr) and polyadenylation signal from simian virus 40 (pA) inserted downstream of the 3'UTR to ensure production of KUN RNA molecules with precise 3'termini for efficient initiation of replication.

In a particularly preferred embodiment, the genetic construct is pKUN1.

In an even more preferred embodiment, the genetic construct is pKUN1 encoding a proline 250 to leucine mutation in an NS1 protein.

***Immunotherapeutic compositions, vaccines and methods of immunization***

A particular aspect of the invention relates to use of an isolated nucleic acid capable of producing infectious Kunjin virus to protectively immunize against at least one another flavivirus.

Accordingly, a vaccine of the invention may be in any of the following forms:

(i) an RNA transcribed from a DNA expression construct of the invention;

(ii) a DNA expression construct of the invention directing transcription of replicating RNA *in vivo*; or

5 (iii) secreted virions produced by transfecting the above RNA or DNA into a permissive cell line such as BHK-21 or Vero, although without limitation thereto.

Virions as described above may be used as a live or killed vaccine as is well understood in the art.

10 The immunotherapeutic composition may further comprise a pharmaceutically-acceptable carrier, diluent or excipient and, optionally, an adjuvant.

By "*pharmaceutically-acceptable carrier, diluent or excipient*" is meant a solid or liquid filler, diluent or encapsulating substance that may be safely used in  
15 systemic administration. Depending upon the particular route of administration, a variety of carriers, well known in the art may be used. These carriers may be selected from a group including sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline and salts such as  
20 mineral acid salts including hydrochlorides, bromides and sulfates, organic acids such as acetates, propionates and malonates and pyrogen-free water.

A useful reference describing pharmaceutically acceptable carriers, diluents and excipients is Remington's Pharmaceutical Sciences (Mack Publishing Co. N.J. USA, 1991) which is incorporated herein by reference.

25 Any safe route of administration may be employed for providing a patient with the composition of the invention. For example, oral, rectal, parenteral, sublingual, buccal, intravenous, intra-articular, intra-muscular, intra-dermal, subcutaneous, inhalational, intraocular, intraperitoneal, intracerebroventricular, transdermal and the like may be employed. Intra-muscular and subcutaneous  
30 injection may be appropriate, for example, for administration of immunotherapeutic compositions, proteinaceous vaccines and nucleic acid vaccines. It is also contemplated that microparticle bombardment may be particularly useful for delivery of nucleic acid vaccines.

Dosage forms include tablets, dispersions, suspensions, injections, solutions, syrups, troches, capsules, suppositories, aerosols, transdermal patches and the like. These dosage forms may also include injecting or implanting controlled releasing devices designed specifically for this purpose or other forms of implants modified to act additionally in this fashion. Controlled release of the therapeutic agent may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose. In addition, the controlled release may be effected by using other polymer matrices, liposomes and/or microspheres.

Immunotherapeutic compositions of the present invention suitable for oral or parenteral administration may be presented as discrete units such as capsules, sachets or tablets each containing a pre-determined amount of one or more therapeutic agents of the invention, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more agents as described above with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the agents of the invention with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

The above compositions may be administered in a manner compatible with the dosage formulation, and in such amount as is pharmaceutically-effective. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial response in a patient over an appropriate period of time. The quantity of agent(s) to be administered may depend on the subject to be treated inclusive of the age, sex, weight and general health condition thereof, factors that will depend on the judgement of the practitioner.

Immunotherapeutic compositions of the invention may be used to prophylactically or therapeutically immunize animals such as humans.

However, other animals are contemplated, preferably vertebrate animals including domestic animals such as livestock and companion animals.

The protective immune response elicited by the vaccine of the invention may include humoral and cellular responses, such as by induction of antibodies, CD8+ CTLs and/or CD4+ T cells.

5 It will also be appreciated that immunotherapeutic compositions and vaccines of the invention may, in certain embodiments, include an adjuvant.

As will be understood in the art, an "*adjuvant*" means one or more substances that enhances the immunogenicity and/or efficacy of a vaccine composition. Non-limiting examples of suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers; detergents such as  
10 Tween®-80; Quil® A, mineral oils such as Drakeol or Marcol, vegetable oils such as peanut oil; *Corynebacterium*-derived adjuvants such as *Corynebacterium parvum*; *Propionibacterium*-derived adjuvants such as *Propionibacterium acne*; *Mycobacterium bovis* (Bacille Calmette and Guerin or BCG); interleukins such as interleukin 2 and interleukin 12; monokines such as interleukin 1; tumour necrosis  
15 factor; interferons such as gamma interferon; combinations such as saponin-aluminium hydroxide or Quil-A aluminium hydroxide; liposomes; ISCOM® and ISCOMATRIX® adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine; Lipid A derivatives; dextran sulfate; DEAE-Dextran or with aluminium  
20 phosphate; carboxypolymethylene such as Carbopol' EMA; acrylic copolymer emulsions such as Neocryl A640 (e.g. U.S. Pat. No. 5,047,238); vaccinia or animal poxvirus proteins; sub-viral particle adjuvants such as cholera toxin, or mixtures thereof.

The present inventors propose that immunization with Kunjin virus will  
25 produce protective, cell-mediated immunity against other flaviviruses such as West Nile virus.

The present invention therefore also contemplates cells isolated from animals, preferably humans, immunized according to the present invention. Isolated cells may be dendritic cells, macrophages and other antigen-presenting  
30 cells, T cells, B cells or any other cells that are involved in the initiation, regulation and/or maintenance of cell mediated immunity. Isolated cells may have efficacy in dendritic cell therapy, production of monoclonal antibodies and adoptive transfer in passive immunization, for example, although without limitation thereto.

So that the invention may be readily understood and put into practical effect, the skilled person is directed the following non-limiting examples.

### EXAMPLES

#### **MATERIALS AND METHODS**

##### **5 Cell culture and virus preparations.**

Vero cells were grown in HEPES-buffered Medium 199 (Gibco) supplemented with antibiotics and 10% FBS and incubated at 37°C. C6/36 cells were cultured in Medium 199 supplemented with antibiotics and 10% FBS and incubated at 28°C and 5% CO<sub>2</sub>. For virus stock production, Vero cells were  
 10 infected with KUN virus (MRM61C strain; 4), WN virus (NY99-4132 strain, obtained from the Division of Vector-Borne Infectious Diseases, Centers for Disease Control, Fort Collins ), or FLSD virus (derived from KUN cDNA clone FLSD; 13, 15) at a multiplicity of infection of 0.1-1 and cultured in medium supplemented with 2% FBS. Culture supernatant was harvested and clarified at  
 15 72-96 h post-infection when 50-70% of cells showed cytopathic effects (CPE). The concentration of infectious virus in stocks was determined by titration on Vero cells in 96-well plates and calculated as the 50% infectious dose (ID<sub>50</sub>)/ml (13). One ID<sub>50</sub> is equivalent to one infectious unit (i.u.).

##### **Plasmid DNA constructs.**

20 Construction of plasmid DNAs pKUN1, coding for the infectious full-length KUN RNA, and pKUN1dGDD, coding for the non-replicating full-length KUN RNA, was described previously (12). In these plasmids, the KUN cDNA sequence is placed under the control of cytomegalovirus early promoter-enhancer region (CMV) to allow *in vivo* transcription of KUN RNA by the cellular RNA  
 25 polymerase II. The plasmids also have the hepatitis delta virus ribozyme sequence (HDVr) inserted immediately after the last nucleotide of KUN cDNA sequence to ensure production of KUN RNAs with the precise 3' terminus, which was shown to be beneficial for more efficient RNA replication (16). The KUN genome in pKUN1 and pKUN1dGDD plasmids is derived from the full-length cDNA clone  
 30 FSDX, that has recently been fully sequenced (17; GeneBank accession No AY274504). The sequence of FLSDX and FLSD cDNA clones is the same and both contain Pro to Leu substitution at amino acid 250 in the NS1 gene. FLSDX clone has 6 other conservative amino acids substitutions compared to the

published sequence of MRM61C strain of KUN virus (17) that did not appear to affect the growth properties of recovered virus.

#### **Mouse immunization and challenge.**

Groups of five to 12 BALB/c mice at 4-5 wks of age were immunized with a total of 0.1, 1 or 10ug of pKUN1 DNA injected intra-muscularly (i.m.) in 2 sites of the thigh muscles. Groups of mice were similarly immunized with 1 or 10ug of defective DNA (pKUN1dGDD). An additional group was immunized by the intra-peritoneal (i.p.) route with a sub lethal dose of  $10^3$  infectious units (i.u.) of attenuated FLSD virus (contains the same genomic sequence as pKUN1 progeny virus) and one group remained unimmunised. At 21 days post immunization, mice from each group were challenged by the intra-cerebral (i.c.) route with  $10^3$  i.u. of the wild type KUN virus (MRM61C strain). Similarly, immunized mice were also challenged with 20 i.u. of West Nile virus (NY99-4132 strain) by either i.c or i.p. route.

The appropriate challenge doses for KUN and WN viruses in 7-8 week old BALB/c mice were previously determined in a pilot study (results not shown). It was observed that i.p. inoculation of 20 i.u. of WN virus was sufficient to produce clear disease symptoms (severely ruffled fur and lethargy) in all animals by 7-8 days post infection. Of these, approximately 60-70% progressed to a more severe form of disease (flaccid hind leg paralysis, hunched posture, moribund ) and were euthanased. In contrast, relatively high doses of the wild type KUN virus inoculated i.p. did not produce consistent rates of morbidity or mortality in these mice. By the i.c. route 20 i.u of WN and 1000 i.u. of KUN viruses were sufficient to produce 80-100% mortality in inoculated mice.

#### **25 Detection of KUN virus in immunized mice.**

For virus detection, 3 mice from each group was tail bled on days 3, 4, 5, 6 and 7 post immunisation under aseptic conditions and blood was allowed to clot overnight at 4°C. The serum was then separated, snap frozen and stored at -70°C until tested. On the day of analysis sera were rapidly thawed then kept on ice. 25 ul of pooled undiluted sera were inoculated in duplicate onto fresh monolayers of C6/36 cells in 96 well plates. After 7 days inoculation the culture supernatant was then carefully removed and replaced with an equal volume of 20% acetone in PBS and the cells allowed to fix for 2 h at 4°C. The fixative was then removed and plates dried at 37°C. Viral antigens were then detected by ELISA (18) using anti-

KUN rabbit antiserum (19). Supernatants from inoculated C6/36 cells were further passaged onto fresh monolayers of C6/36 cells and the process repeated to detect progeny virus.

#### Measurement of serum antibody responses.

- 5 For detection of virus-specific antibody in sera, mouse blood was collected by tail bleed at 19 days post inoculation, held at 4°C overnight to clot, serum was separated and snap frozen at -70°C until tested. Sera from each mouse group were pooled and titrated in doubling dilutions in fixed-cell ELISA against the viral proteins of wild type KUN virus and WN virus as previously described (20).  
 10 The reciprocal of the serum dilution that produced an OD of at least 0.3 on viral antigen and at least 0.2 higher than that produced on control antigen (fixed uninfected cells) was deemed the ELISA titre of each sample.

#### Microneutralization assays.

- Sera samples were tested for neutralization of KUN and WN viruses by  
 15 microneutralisation assay as described previously (21). Briefly, sera from each mouse group were pooled, heat-inactivated at 56°C and serially diluted two-fold in cell growth medium. Twenty-five µl of each dilution was then added in duplicate to wells of a 96 well culture plate. An equal volume of growth medium containing approximately 100 i.u. of virus was then added to each well, and plates  
 20 were allowed to incubate at 37°C with occasional gentle agitation. Fifty µl of growth media containing approximately 10<sup>4</sup> Vero cells were then added to each well and plates incubated at 37°C for 5 days. The reciprocal of the serum dilution that inhibited the formation of viral cytopathic effects was deemed the neutralization titre.

#### 25 Kunjin virus replication kinetics

- Vero cells (african green monkey kidney cells) and C6/36 (*Aedes albopictus*) cells cultured in 12-well plates were infected with either wild-type Kunjin virus clone 250PRO (proline at residue 250 of NS1), FLSD (leucine at residue 250 of NS1), 250A (alanine at residue 250 of NS1) or 250V (valine at  
 30 residue 250 of NS1) at a multiplicity of infection (MOI) of 0.1. Two hours post-infection the culture fluid was removed from the cells and they were washed twice with 2mL of PBS. 2mL of fresh media supplemented with 2% FBS was added to each well and samples were harvested at regular intervals until 72 hours post-infection. The samples were stored immediately at -70°C.

### Titration of Viruses

Serial ten-fold dilutions were made from the virus sample in culture media and 50 $\mu$ L of each dilution of virus was added to 10 wells of a 96 well plate containing confluent vero cells. At 7 days post-infection the wells of the plate exhibiting cytopathic effect (CPE) were recorded and this data was used to calculate the 50% tissue culture infectious dose (TCID<sub>50</sub>) of the initial virus sample using the Reed-Muench equation. Fixed-cell ELISA was used to corroborate the TCID<sub>50</sub> data obtained by visual inspection of CPE.

### RESULTS

#### 10 Replication kinetics of virus mutants at amino acid 250 in the NS1 protein.

Proline to leucine, alanine or valine mutations at residue 250 of NS1 were investigated with regard to Kunjin virus replication kinetics in C6/36 cells (Figure 1) and in Vero cells (Figure 2). The data show that all three mutations at residue 250 resulted in delayed viral replication, with the valine mutation resulting in the lowest level of infectious virus and slightly longer delay than the alanine mutation. It is proposed that either of these NS1 mutations could be used for attenuating Kunjin virus for the purpose of immunizing against another flavivirus according to the present invention.

#### Injection of pKUN1 DNA induces low level viraemia in mice.

20 We showed previously that transfection of pKUN1 DNA directing transcription of replication-competent full-length KUN RNA but not of pKUN1dGDD DNA directing transcription of replication-deficient full-length KUN RNA into BHK cells resulted in production of secreted infectious KUN virus (12). We examined whether injection of pKUN1 DNA into mice would lead to production of infectious virus *in vivo*. Groups of mice were injected i.m. with different doses of pKUN1 DNA or injected i.p. with a sublethal dose (1000 i.u.) of attenuated KUN FLSD virus. FLSD virus was prepared in BHK cells transfected with FLSD RNA (13) that has a genomic sequence identical to that expected to be present in the pKUN1-derived virus and containing proline to leucine mutation at amino acid 250 in the NS1 protein. The sera from injected mice were tested for the presence of infectious KUN virus between 3 and 7 days post injection, by inoculation of C6/36 and Vero cell cultures.



KUN virus was isolated after the second passage of culture supernatant from mosquito cells initially inoculated with undiluted mouse serum collected at 4 days post injection with 0.1 ug of pKUN1 DNA, and at 3 days post injection with 1 ug of pKUN1 DNA (Table 1). In the group injected i.p. with FLSD, progeny virus was detected after secondary passage of mouse serum samples collected at 3, 4, and 5 days after FLSD injection. No virus was isolated from mice that received 10ug of pKUN1 DNA or 10ug of pKUN1dGDD (defective) DNA. Although serum samples were not titrated, the observation that virus was not detected in the first passage on C6/36 cells of undiluted mouse sera collected from each experimental group, indicated that only trace amounts of virus were present in samples positive on the second passage..

Analysis of virus recovered from animals vaccinated i.m. with pKUN1 DNA confirmed that the attenuating leucine mutation at NS1 residue 250 was retained, along with the monomeric NS1 phenotype (results not shown). In addition, the nucleotide sequence spanning the entire NS1 gene (approximately 1000 nucleotides) was identical with the corresponding sequence of the pKUN1 DNA used to immunize the animals, indicating that the viral RNA was transcribed from the plasmid with high fidelity *in vivo* (results not shown).

The data presented herein demonstrate that i.m. injection of as little as 0.1 ug of pKUN1 DNA resulted in production of infectious, but non-lethal KUN virus in adult mice.

**Immunization with pKUN1 DNA induces neutralizing antibody to New York strain of WN virus.**

Nineteen days after immunization, mice were bled and sera from each group pooled and tested for antibody to wild type KUN virus in ELISA and by micro-neutralization assay. Sera from mice immunized i.p. with 1000 i.u. of KUN FLSD virus showed the highest titer to KUN antigens in ELISA (1280), while sera from mice receiving i.m. injection of 0.1, 1, or 10ug of pKUN 1 DNA displayed ELISA titers of 160, 320, and 320 respectively (Table 2). KUN-specific antibody responses in unimmunized mice or mice receiving defective DNA could not be detected (ELISA titer <40). Neutralizing antibody to KUN virus was also detected in sera of mice immunized with pKUN1 DNA (titers of 10-20) or FLSD virus (40). Slightly higher levels of antibody as measured by ELISA and virus

neutralization correlated with a longer period of viraemia in FLSD-immunized mice (see Table 1).

Sera from mice immunized with FLSD virus and with KUN plasmid DNAs were then tested for reactivity with viral antigens of the New York strain of WN virus in ELISA and for neutralization of the New York strain of WN virus *in vitro*. Slightly lower ELISA titers to WN antigen compared to that of KUN antigen were recorded for mice immunized with each dose of pKUN1 DNA (80) or FLSD virus (640). However similar neutralizing titers were observed (Table 2).

Thus, the results presented in this section clearly demonstrate that immunization with pKUN1 plasmid DNA induces cross-reactive antibodies that are able to neutralize the New York strain of WN virus with efficiency similar to that observed for neutralization of KUN virus.

**Immunization with pKUN1 DNA protects mice against the New York strain of WN virus.**

In the first series of protection experiments we wished to establish whether immunization with pKUN1 DNA would protect mice against i.c. challenge with the wild type strain of KUN virus. Three weeks after a single immunization with pKUN1 or pKUN1dGDD DNAs or with attenuated FLSD virus, mice were challenged i.c. with 1000 infectious units of the wild type KUN virus (MRM61C strain). Animals immunized with 1 or 10 ug of pKUN1 DNA or with 1000 i.u. of FLSD virus were solidly protected from challenge (80-100% survival), while unimmunized mice or those receiving defective pKUN1dGDD DNA were highly susceptible to the challenge (only 20% survival) (Table 3). Survival of 2/5 (40%) of mice immunized with 0.1 ug of pKUN1 DNA indicated partial protection, but this result was not statistically significant.

To determine whether immunization with KUN DNA and attenuated FLSD virus would also protect mice from West Nile virus, immunized animals were challenged i.p. or i.c. with a lethal dose (20 i.u.) of the virulent New York strain (NY99 4132). Mice immunized with FLSD or 1ug of pKUN 1 DNA were completely protected (100% survival) against i.c. challenge with West Nile virus, while 0.1 ug of pKUN1 DNA induced partial protection (Table 3.). On the other hand, unimmunized mice or those immunized with the defective KUN DNA were highly susceptible (90% mortality). Similarly, mice immunized with FLSD virus

or pKUN 1 DNA were solidly protected from morbidity or mortality compared to controls when challenged i.p. with WN virus (Table 3).

The pKUN1 cDNA used according to the present invention is derived from a previously described FLSDX clone which differed from another closely related clone, pAKUN, by about 100,000 fold as measured by specific infectivity of  
 5 corresponding *in vitro* transcribed RNA (15). We have previously confirmed the retention of the introduced mutation in NS2A gene (Arg175 to Lys) in the recovered AKUN virus (29), however the rest of the sequence of pAKUN cDNA and of the recovered AKUN virus, as well as of FLSDX cDNA (except for NS1  
 10 gene, (30) has not been determined. It was reasonable to assume that low specific infectivity of pAKUN RNA was due to the presence of mutations inhibiting virus replication and/or assembly, and that these mutations were corrected in the recovered AKUN virus. It was also likely that these inhibiting mutations originally present in pAKUN cDNA were corrected in FLSDX cDNA leading to  
 15 dramatic improvement in specific infectivity of FLSDX RNA.

To confirm the above assumption we decided to determine the entire genomic sequence of pAKUN and FLSDX cDNA clones and compare them with the previously published sequence of MRM61C strain of KUN virus (Genebank accession No. D 00246) (6). The differences between pAKUN, FLSDX and the  
 20 published KUN sequence are shown in Table 4. FLSDX cDNA had 13 nucleotides different to the published KUN sequence with seven of them leading to amino acid changes; pAKUN cDNA had 17 nucleotides different to the published KUN sequence with 11 of them leading to amino acid changes. These amino acid mutations were scattered throughout entire coding region and were  
 25 located in prM, E, NS1, NS2A, NS3 and NS4B genes. No mutations were found in NS2B, NS4A, NS5 and in the 5' and 3' UTRs. pAKUN and FLSDX cDNA clones had six common amino acid substitutions, mainly conserved, which were different from the original MRM61C published sequence (Table 4). These six common amino acids detected in both FLSDX and pAKUN sequences, aligned  
 30 better with the sequences of other flaviviruses from the same subgroup than with the published MRM61C sequence, suggesting that they represent corrected errors in the originally published MRM61C sequence. The Pro250 to Leu codon change in the NS1 gene was present in both pAKUN and FLSDX cDNAs and apparently contributed to delayed replication of recovered viruses (30). Thus, with the

exclusion of one amino acid difference in NS1 (Pro250 to Leu) that apparently arose during cloning, FLSDX cDNA was identical to the corrected wt KUN RNA sequence.

One of two mutations in NS2A in pAKUN clone represented a conserved amino acid change (Arg175 to Lys) which was introduced intentionally as a marker mutation during plasmid construction. We demonstrated previously that this mutation was retained in the recovered AKUN virus and did not affect viral replication (29). Thus, it left only 3 amino acid codons in pAKUN cDNA different to those in FLSDX cDNAs and/or to those in corrected MRM61C viral RNA sequences (nucleotide 3701T to A, changing NS2A amino acid Ile59 to Asn; nucleotide 6163T to C, changing NS3 amino acid Tyr518 to His; nucleotide 6280T to C, changing NS3 amino acid Ser557 to Pro) (Table 4). These changes apparently contributed to the low specific infectivity of transcribed pAKUN RNA. To examine whether these mutations were present in RNA of the recovered AKUN virus we performed RT-PCR and sequence analysis of the corresponding genomic regions in viral RNA. The results showed that all these three mutations but not the marker mutation (Arg175 to Lys in NS2A) were reverted back to the wild type sequence in the recovered viral RNA (data not shown), clearly demonstrating the importance of these amino acid residues in virus replication.

## DISCUSSION

In a previous report we showed that immunization of mice with plasmid DNA coding for a self-replicating subgenomic (replicon) KUN RNA expressing heterologous CTL epitopes resulted in induction of epitope-specific CTL responses (22). Here we demonstrate that immunization of mice with plasmid DNA encoding the attenuated but infectious full-length KUN RNA provides protective immunity against challenge with the wild type KUN virus, and most importantly, against challenge with the highly pathogenic NY99 strain of West Nile virus. Apparently, replication of viral RNA produced in pKUN1 DNA-transfected cells and spread of the infectious progeny virus to nearby cells, allows sufficient virus amplification in the inoculated animal to produce a protective immune response that is similar in magnitude to that observed during natural virus infection. However, the limited replication of the attenuated pKUN1 progeny virus, and low amounts of infectious virus observed in mouse serum would likely preclude virus transmission to arthropod vectors, thus making the vaccine safer.

Our inability to detect virus in serum between 3 and 7 days post-immunization with the highest dose (10ug) of pKUN1 DNA suggests that a rapid, transient viremia may have occurred during the first 72h prior to the testing period. This is consistent with our detection of virus at only a single time point in serum after immunization with 1ug (day 3) and 0.1 ug doses (day 4). In contrast, i.p. injection of FLSD virus resulted in a viremia of at least 3 days duration (days 3 - 5). The difference between the routes of injection for plasmid DNA (i.m) and for virions (i.p.) may account for the observed differences in the longevity of viremia.

While as little as 0.1-1ug of pKUN1 DNA was sufficient to induce protective immunity, mice immunized with 1-10ug of the defective plasmid DNA construct (pKUN1dGDD) failed to generate a detectable humoral response. This suggests that the amounts of viral proteins produced from a messenger KUN RNA transcribed under direction of a CMV promoter are insufficient to induce protective immunity. This is consistent with previous reports using DNA-based subunit flavivirus vaccines expressing the prM-E structural genes of Japanese encephalitis virus (23), Murray Valley encephalitis virus (24) and WN virus (25). These studies reported that 50 - 100ug doses were required to elicit protective immunity by a single injection via the i.m. route. The efficacy of the WN subunit vaccine could be significantly enhanced by performing co-electrotransfer on the inoculated muscle tissue immediately after the injection (25). This reduced the effective dose in mice to 1 or 0.1 ug, similar to the efficacy of the pKUN 1 DNA (injected into muscle without co-electrotransfer) observed in our study. It is also worth noting that a significant advantage of a vaccine expressing the full length flavivirus genome over the E-prM subunit, is that humoral responses to the NS1 protein and cell-mediated responses to NS3 epitopes may also contribute to more efficient viral clearance and protection (20, 26, 27).

In Australia, KUN virus is widespread and endemic in some areas. However, overt infection in man is extremely rare and nonfatal (10) demonstrating natural attenuation of this virus in humans. KUN virus has been extensively studied for over 30 years and these studies, particularly in molecular biology of virus replication, provided major benchmarks for other flaviviruses (28). The neutralizing antibody responses to KUN virus and their cross-reactivity are well documented (4). Moreover, we have recently demonstrated that KUN

virus is genetically and antigenically very closely related to the North American strain of WN virus (2, 8). Indeed, reactions of a panel of monoclonal antibodies produced to KUN virus have revealed that the majority of antibody binding sites on the viral E protein are conserved between the two viruses, including those determinants that elicit neutralizing antibodies (2, 8, Hall *et al.*, unpublished results). These data support the presented results showing that pKUN1- and FLSD-immunized mice were protected from both KUN and WN virus challenge and developed an antibody response that neutralized both viruses with similar efficiency *in vitro*.

Despite the high degree of homology between the two viruses, studies by Beasley *et al.* (11) have demonstrated that wild-type KUN virus is significantly less virulent in adult NIH Swiss mice than the New York strain of West Nile by peripheral inoculation. These findings agree with our inability to produce consistent mortality rates in adult BALB/c mice after inoculation with KUN virus by the i.p. route (results not shown). The inclusion of a stable proline to leucine mutation at residue 250 in the NS1 protein, shown to attenuate KUN virus in mice (13), into the pKUN1 DNA vaccine backbone should result in further attenuation of the KUN virus-based vaccine, while retaining highly efficient protective immunity.

## Conclusions

The rapid spread of West Nile virus across the North American continent during 2002, has resulted in numerous fatal cases of human and equine disease (3, [www.cdc.gov/ncidod/dvbid/westnile/index.htm](http://www.cdc.gov/ncidod/dvbid/westnile/index.htm)). Consequently, an effective and safe vaccination strategy against the virus is urgently being sought for both medical and veterinary purposes. The very close antigenic relationship that KUN virus shares with the North American strain of WN virus makes it an attractive vaccine candidate. The naturally attenuated phenotype, stable genetics and well studied ecology, epidemiology and molecular biology of KUN virus provide a solid background for vaccine derivation. The safety of a KUN-based vaccine is further enhanced by the inclusion of a well characterized, stable attenuative mutation. The presented results demonstrating that mice vaccinated with pKUN1 DNA were protected from a challenge with the lethal doses of the New York strain of West Nile virus, suggest that immunization with KUN virus-based

plasmid DNA may provide a rapid, convenient and effective vaccination strategy against further outbreaks of WN virus.

Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one  
5 embodiment or specific collection of features. It will therefore be appreciated by those of skill in the art that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention.

All computer programs, algorithms, patent and scientific literature referred  
10 to herein is incorporated herein by reference.

---

# REFERENCES

1. Murgue, B. Zeller, H. and Deubel, V. (2002) *Curr. Top. Microbiol. Immunol.* **267**, 195-221.
  2. Lanciotti, R.S., Roehrig, J.T., Deubel, V., Smith, J., Parker, M., Steele, K., Volpe, K.E., Crabtree, J.H., Scherret, J.H., Hall, R.A., Mackenzie, J.S., Cropp, C.B., Panigrahy, B., Ostlund, E., Schmitt, B., Malkinson, M., Banet, C., Weisman, J., Komar, N., Savage, H.M., Stone, W., McNamara, T., & Gubler, D.J. (1999). *Science* **286**, 2333-2337.
  3. Roehrig, J.T., Layton, M., Smith, P., Campbell, G.L., Nasci, R. & Lanciotti, R.S. (2002). *Curr. Top. Microbiol. Immunol.* **267**, 223-240.
  4. Westaway, E.G. (1968). *J. Immunol.* **100**, 569-580.
  5. Hall, R.A., Burgess, G.W., Kay, B.H. and Clancy, P. (1991) *Immunol. Cel. Biol.* **69**, 47-49.
  6. Coia, G., Parker, M.D., Speight, G., Byrne, M.E. & Westaway, E.G. (1988). *J. Gen. Virol.* **69**, 1-21.
  7. Lanciotti, R.S., Ebel, G.D., Deubel, V., Kerst, A.J., Murri, S., Meyer, R., Bowen, M., McKinney, N., Morrill, W.E., Crabtree, M.B., Kramer, L.D., & Roehrig, J.T. (2002) *Virology* **298**, 96-105.
  8. Scherret, J.H., Poidinger, M., Mackenzie, J.S., Broom, A.K., Deubel, V., Lipkin, W.I., Briese, T., Gould, E.A., & Hall, R.A. (2001). *Emerg. Infect. Dis.* **7**, 697-705.
  9. Heinz, F.X., Collett, M.S., Purcell, R.H., Gould, E.A., Howard, C.R., Houghton, M., et al (2000) 7th Report of the International Committee for the Taxonomy of Viruses. Academic Press, San Diego, pp 859-878.
  10. Hall, R.A., Broom, A.K., Smith, D.W., & Mackenzie, J.S. (2002). *Curr. Top. Microbiol. Immunol.* **267**, 253-269.
  11. Beasley, D.W., Li, L., Suderman, M.T., Barrett, A.D. (2002) *Virology* **296**, 17-23.
  12. Khromykh, A.A., Varnavski, A.N., Sedlak, P.L., Westaway, E.G. (2001) *J. Virol.* **75**, 4633-4640.
  13. Hall, R.A., Khromykh, A.A., Mackenzie, J.M., Scherret, J., Khromykh, T.I., Poidinger, M., & Mackenzie, J.S. (1999). *Virology*, **264**, 66-75.
  14. Ward, G., Rieder, E. & Mason PW. (1997) *J. Virol.* **71**, 7442-7447.
-



15. Khromykh, A. A., Kenney, M. T. & Westaway, E. G. (1998). *J. Virol.* **72**, 7270-7279.
16. Varnavski, A.N, Young, P. R., & Khromykh, A.A. (2000). *J. Virol.* **74**, 4394-4403.
17. Liu W.J., Chen H.B, & Khromykh A.A..(2003) *J.Virol.* **77**, issue 14 (in press).
18. Adams, S. C., Broom, A. K., Sammels, L. M., Hartnett, A. C., Howard, M. J., Coelen, R. J., Mackenzie, J. S. & Hall R. A. (1995). *Virology* **206**, 49-56.
19. Hall, R.A., Broom, A.K., Howard, M.J., Hartnett, A.C. & Mackenzie, J.S. *J. Virol. Meths.* **51**, 201-210.
20. Hall, R.A., Brand, T.N., Lobigs, M., Sangster, M.Y., Howard, M.J., Mackenzie, J.S. (1996) *J. Gen. Virol.* **77**, 1287-1294.
21. Hall, R. A., Kay, B. H., Burgess, G. W., Clancy, P. & Fanning, I. D. (1990). *J. Gen. Virol.* **71**, 2923-2930.
22. Anraku. I., Harvey, T.J., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A., & Khromykh, A.A. (2002) *J. Virol.* **76**, 3791-3799.
23. Chang, G.J., Hunt, A.R., & Davis, B. (2000) *J.Virol.* **74**, 4244-4252.
24. Colombage, G., Hall, R., Pavy, M. & Lobigs, M. (1998) *Virology*, **250**, 151-163.
25. Davis, B.S., Chang, G.J, Cropp, B., Roehrig, J.T., Martin, D.A., Mitchell, C.J., Bowen, R., & Bunning, M.L. (2001) *J. Virol.* **75**, 4040-4047.
26. Parish, C.R., Coia, G., Hill, A., Mullbacher, A., Westaway, E.G. & Blanden, R.V. (1991) *J. Gen. Virol.*, **72**, 1645-1653.
27. Lobigs, M., Arthur, C.E., Mullbacher, A. & Blanden, R.V. (1993) *Virology*, **202**, 195-201.
28. Westaway, E.G., Mackenzie, J. M., & Khromykh, A.A. (2002). *Curr. Top. Microbiol. Immunol.* **267**, 324-351.
29. Khromykh, A. A., and E. G. Westaway. 1994. *J Virol.* **68**, 4580-4588.
30. Khromykh, A. A., A. N. Varnavski, and E. G. Westaway. 1998.. *J Virol.* **72**, 5967-5977.

Table 1. Isolation of KUN virus from mouse sera collected at various times post injection with KUN DNAs or with attenuated FLSD virus

Immunogen	Days post immunisation <sup>#</sup>				
	Day 3	Day 4	Day 5	Day 6	Day 7
FLSD virus	+++	+++	+	-	-
0.1ug pKUN1	-	+++	-	-	-
1ug pKUN1	+	-	-	-	-
10ug pKUN1	-	-	-	-	-
10ug pKUN1dGDD	-	-	-	-	-
Unimmunized	-	-	-	-	-

<sup>#</sup> Attenuated FLSD virus (1000 i.u.) was injected i.p., DNAs were injected i.m.

Virus was detected in both (\*\*) or one (\*) of duplicate wells of C6/36 cells after secondary passage from cultures inoculated with pooled mouse serum.

Table 2. Detection of antibodies to KUN and WN viruses in sera\* from immunized mice by ELISA and by virus neutralization assays.

Mouse group	Neutralization titers		ELISA titers	
	KUN	WN	KUN	WN
Unimmunized	<10	<10	<40	<40
10ug pKUN1dGDD	<10	<10	<40	<40
0.1 ug pKUN1	10	10	160	80
1 ug pKUN1	20	20	320	80
10 ug pKUN1	20	20	320	80
1000 i.u. FLSD	40	80	1280	640

\* Mice were bled 19 days after a single immunization

Table 3. Protection of immunized mice from lethal challenge with NY99 WN and KUN viruses

Mouse group	% morbidity and mortality after i.p. challenge with NY99 WN virus (20 i.u.)*		% mortality after i.c. challenge with KUN or NY99 WN viruses*	
	% morbidity** (sick/challenged)	% mortality@ (dead/challenged)	WN, 20 i.u. (dead/challenged)	KUN, 10 <sup>3</sup> i.u. (dead/challenged)
Control (unimmunized)	100 (11/11)	64 (7/11)	89 (8/9)	80 (4/5)
10 ug pKUN1dGDD DNA#	ND	ND	ND	80 (4/5)
1 ug pKUN1dGDD DNA#	75 (9/12)	58 (7/12)	90 (9/10)	ND
0.1ug pKUN1 DNA#	16 (2/12)	8 (1/12)	33 (2/6)	60 (3/5)
1ug pKUN1 DNA#	8 (1/12)	8 (1/12)	0 (0/10)	0 (0/5)
10ug pKUN1 DNA#	ND	ND	ND	20 (1/5)
1000 i.u. FLSD virus##	0 (0/12)	0 (0/12)	0 (0/10)	20 (1/5)

\* Mice were challenged i.p. or i.c. three weeks after a single immunization

\*\* Percentage of mice that developed symptoms of fever (severely ruffled fur and lethargy)

@ Percentage of mice that progressed to symptoms of encephalitis (hunched posture, flaccid hindleg paralysis, moribund)

# Mice were immunized i.m. with varying doses of pKUN1 or pKUN1dGDD DNA at 4-5 weeks of age.

## Mice were immunized i.p. at 4-5 wks of age.

ND not don

Table 4. Differences between the published KUN MRM61C sequences and the sequences of infectious KUN cDNA clones

Nucleotide position	Gene	Amino acid position in encoded protein	MRM61C		FLSDX cDNA		pAKUN cDNA		Corresponding residue in related flaviviruses
			Nucleotide	Amino acid	Nucleotide	Amino acid	Nucleotide	Amino acid	
544	PrM	28	C <sup>a</sup>	Pro	A	Thr	A	Thr	Thr (WN,JE,MVE)
1500	E	178	G	Leu	T <sup>c</sup>	-	-	-	Leu(WN,JE) / Ala(MVE)
1635	E	223	C	Leu	-	-	T	-	Leu(WN,MVE,JE)
1824	E	286	C	Leu	G	-	G	-	Leu(WN,MVE,JE)
2556	NS1	29	T <sup>a</sup>	Ile	G	Met	G	Met	Ile(MVE) / Met (WN) / Val (JE)
2924	NS1	152	A <sup>a</sup>	Asn	G	Ser	G	Ser	Ser(WN,MVE,JE)
3218	NS1	250	C	Pro	T <sup>b</sup>	Leu	T <sup>b</sup>	Leu	Pro(WN,MVE,JE)
3701	NS2A	59	T	Ile	-	-	A <sup>b</sup>	Asn	Ile(WN,MVE) / Val (JE)
4049	NS2A	175	G	Arg	-	-	A <sup>c</sup>	Lys	Arg(WN,MVE,JE)
5937	NS3	442	A	Val	G	-	G	-	Val(WN,MVE,JE)
5996	NS3	462	C <sup>a</sup>	Thr	T	Ile	T	Ile	Ile (WN) / Val (JE,MVE)
6017	NS3	469	C <sup>a</sup>	Ala	T	Val	T	Val	Val (WN,JE) / Ile (MVE)
6163	NS3	518	T	Tyr	-	-	C <sup>b</sup>	His	Tyr (WN,MVE) / Phe (JE)
6280	NS3	557	T	Ser	-	-	C <sup>b</sup>	Pro	Ser (WN) / Gln (JE,MVE)
7112	NS4B	66	C <sup>a</sup>	Thr	A	Asn	A	Asn	Asn (WN) / Thr(MVE,JE)
7293	NS4B	126	G	Val	A	-	A	-	Val(WN) / Leu(MVE,JE)
7785	NS5	35	C	Val	T	-	T	-	Val(WN,MVE,JE)
10197	NS5	839	C	Ser	T	-	T	-	Ser(WN) / Thr (JE,MVE)

**LEGEND TO TABLE 4**

Nucleotides in bold in cDNA clones indicate changes from the original published sequence which lead to changes in corresponding amino acids, also shown in bold.

"-" shows no differences from wild type in the indicated nucleotide or in the corresponding encoded amino acid

<sup>a</sup> – apparent errors in the published MRM61C

<sup>b</sup> – mutations probably introduced during cloning


<sup>c</sup> – mutation introduced to produce cDNA clone

WN-west Nile virus, JE-Japanese encephalitis virus, MVE-Murray Valley encephalitis virus.


pAKUN and FLSDX cDNA sequences have been deposited to GeneBank and obtained accession numbers AY274505 and AY274504, respectively

---

1/2



**FIG. 1**

**FIG. 2**

**Application Data Sheet**  
**APPLICATION INFORMATION**

Application Number::  
Filing Date:: 10/29/03  
Application Type:: Provisional  
Subject Matter:: Utility  
Suggested classification::  
Suggested Group Art Unit::  
CD-ROM or CD-R?:: None  
Number of CD Disks:  
Number of Copies of CDs::  
Sequence Submission?::  
Computer Readable From (CRF)?:: No  
Number of Copies of CRF::  
Title:: WEST NILE VIRUS VACCINE  
Attorney Docket Number:: 224997  
Request for Early Publication?:: No  
Request for Non-Publication?:: No  
Suggested Drawing Figure::  
Total Drawing Sheets::  
Small Entity?:: Yes  
Latin Name::  
Variety denomination name::  
Petition Included?:: No  
Petition Type::  
Licensed US Govt. Agency::  
Contract or Grant Numbers::  
Secrecy Order in Parent Appl.?:: No

**APPLICANT INFORMATION**

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Australia



Status:: Full Capacity  
Given Name:: Alexander  
Middle Name:: A  
Family Name:: Khromykh  
Name Suffix::  
City of Residence:: The Gap  
State or Prov. of Residence:: Queensland  
Country of Residence:: Australia  
Street of mailing address:: 12 Devonhill Street

City of mailing address:: The Gap  
State or Province of mailing address:: Queensland  
Country of mailing address:: Australia  
Postal or Zip Code of mailing address:: 4061  
Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Australia  
Status:: Full Capacity  
Given Name:: Royal  
Middle Name:: Alexander  
Family Name:: Hall  
Name Suffix::  
City of Residence:: Graceville  
State or Prov. of Residence:: Queensland  
Country of Residence:: Australia  
Street of mailing address:: 4 Haldane Street

City of mailing address:: Graceville  
State or Province of mailing address:: Queensland  
Country of mailing address:: Australia  
Postal or Zip Code of mailing address:: 4075

#### **CORRESPONDENCE INFORMATION**

Correspondence Customer Number:: 23460  
Phone:: (312) 616-5600  
Fax:: (312) 616-5700  
E-mail Address:: mail@leydig.com

#### **REPRESENTATIVE INFORMATION**

Representative Customer Number:: 23460

Representative Designation::      Registration Number::      Representative Name::  
Primary  
Associate

#### **DOMESTIC PRIORITY INFORMATION**

Application::      Continuity Type::      Parent Application::      Parent Filing Date::

#### **FOREIGN APPLICATION INFORMATION**

Country::      Application Number::      Filing Date::      Priority Claimed

#### **ASSIGNEE INFORMATION**

Assignee name::      The University of Queensland  
Street of mailing address::

City of mailing address::      Brisbane

State or Province of  
mailing address::      Queensland

Country of mailing  
address::      Australia

Postal or Zip Code of  
mailing address::      4072